Study Of Palbociclib (PD-0332991) In Renal Impairment

Summary

Since the amount of palbociclib eliminated in urine is 6.9%, renal impairment is not expected to have much impact on palbociclib. However, the Federal Drug Administration (FDA) Guidance recommends a study in subjects with renal impairment when the drug is likely to be used in patients with impaired renal function. Palbociclib is intended for chronic use in cancer patients who may have some degree of impaired renal function.

Timeline

Start

2014-05

Primary completion

2016-05

Completion

2016-05

Drugs

Indications